feed,title,long_url,short_url
FDA:MedWatch,"Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication -Â Initial Safety Trial Results Find Increased Risk of Serious Heart-related Problems and Cancer with Arthritis and Ulcerative Colitis Medicine",http://www.fda.gov/safety/medical-product-safety-information/xeljanz-xeljanz-xr-tofacitinib-drug-safety-communication-initial-safety-trial-results-find-increased,https://j.mp/3tmwibv
